Keyphrases
Advanced Breast Cancer
100%
Fulvestrant
100%
Postmenopausal Patients
100%
Aromatase Inhibitors
100%
Letrozole
50%
Everolimus
33%
Randomized Phase II Trial
33%
Non-steroidal
33%
Endocrine Therapy
33%
ER-positive
16%
Conventional Treatment
16%
Trial Reporting
16%
Neoadjuvant Setting
16%
Anastrozole
16%
PubMed
16%
Patient Selection
16%
Breast Cancer
16%
Inclusion Criteria
16%
Cyclin-dependent Kinase 6 (CDK6)
16%
Progression-free Survival
16%
Specific Settings
16%
First-line Regimen
16%
Cancer Clinical Trials
16%
Overall Survival
16%
Randomized Phase III Trial
16%
Estrogen Receptor
16%
Refractory Patients
16%
Treatment Options
16%
Median Progression-free Survival
16%
Inappropriate Treatment
16%
Endocrine Treatment
16%
Medicine and Dentistry
Fulvestrant
100%
Aromatase Inhibitor
100%
Breast Cancer
100%
Hormone Therapy
50%
Letrozole
50%
Progression Free Survival
33%
Everolimus
33%
Biological Marker
16%
Anastrozole
16%
Cyclin-Dependent Kinase 4
16%
Phase II Trials
16%
Health Care Cost
16%
Overall Survival
16%
Recurrent Disease
16%
Hormone Receptor
16%
Estrogen Receptor
16%
Mechanistic Target of Rapamycin
16%
Tamoxifen
16%
Pharmacology, Toxicology and Pharmaceutical Science
Aromatase Inhibitor
100%
Fulvestrant
100%
Breast Cancer
100%
Letrozole
50%
Everolimus
33%
Progression Free Survival
33%
Endocrine Therapy
33%
Exemestane
33%
Estrogen Receptor
16%
Hormone Receptor
16%
Phase II Trials
16%
Anastrozole
16%
Overall Survival
16%
Recurrent Disease
16%
Biological Marker
16%
Mammalian Target of Rapamycin
16%
Tamoxifen
16%